247 related articles for article (PubMed ID: 29369779)
1. EphB4: A promising target for upper aerodigestive malignancies.
Salgia R; Kulkarni P; Gill PS
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):128-137. PubMed ID: 29369779
[TBL] [Abstract][Full Text] [Related]
2. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
Ferguson BD; Carol Tan YH; Kanteti RS; Liu R; Gayed MJ; Vokes EE; Ferguson MK; John Iafrate A; Gill PS; Salgia R
Sci Rep; 2015 Jun; 5():10641. PubMed ID: 26073592
[TBL] [Abstract][Full Text] [Related]
3. Targeting receptor tyrosine kinase EphB4 in cancer therapy.
Chen Y; Zhang H; Zhang Y
Semin Cancer Biol; 2019 Jun; 56():37-46. PubMed ID: 28993206
[TBL] [Abstract][Full Text] [Related]
4. Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
Ferguson BD; Tretiakova MS; Lingen MW; Gill PS; Salgia R
Growth Factors; 2014 Dec; 32(6):202-6. PubMed ID: 25391996
[TBL] [Abstract][Full Text] [Related]
5. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Masood R; Kumar SR; Sinha UK; Crowe DL; Krasnoperov V; Reddy RK; Zozulya S; Singh J; Xia G; Broek D; Schönthal AH; Gill PS
Int J Cancer; 2006 Sep; 119(6):1236-48. PubMed ID: 16615113
[TBL] [Abstract][Full Text] [Related]
6. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
7. A narrative review of the role of Eph receptors in head and neck squamous cell carcinoma.
Al-Jamaei AAH; Subramanyam RV; Helder MN; Forouzanfar T; van der Meij EH; Al-Jamei S; de Visscher JGAM
Oral Dis; 2024 Apr; 30(3):833-845. PubMed ID: 37279081
[TBL] [Abstract][Full Text] [Related]
8. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
Ferguson BD; Liu R; Rolle CE; Tan YH; Krasnoperov V; Kanteti R; Tretiakova MS; Cervantes GM; Hasina R; Hseu RD; Iafrate AJ; Karrison T; Ferguson MK; Husain AN; Faoro L; Vokes EE; Gill PS; Salgia R
PLoS One; 2013; 8(7):e67668. PubMed ID: 23844053
[TBL] [Abstract][Full Text] [Related]
9. Expression of Ephb2 and Ephb4 in breast carcinoma.
Wu Q; Suo Z; Risberg B; Karlsson MG; Villman K; Nesland JM
Pathol Oncol Res; 2004; 10(1):26-33. PubMed ID: 15029258
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IR
Scalia P; Pandini G; Carnevale V; Giordano A; Williams SJ
Oncogene; 2019 Aug; 38(31):5987-6001. PubMed ID: 31270394
[TBL] [Abstract][Full Text] [Related]
11. Expression of EphB4 in head and neck squamous cell carcinoma.
Sinha UK; Kundra A; Scalia P; Smith DL; Parsa B; Masood R; Gill PS
Ear Nose Throat J; 2003 Nov; 82(11):866, 869-70, 887. PubMed ID: 14661437
[TBL] [Abstract][Full Text] [Related]
12. HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma.
Wang Y; Jiang Z; Yan J; Ying S
Dis Markers; 2019; 2019():4183157. PubMed ID: 30891101
[TBL] [Abstract][Full Text] [Related]
13. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.
Jensen DH; Dabelsteen E; Specht L; Fiehn AM; Therkildsen MH; Jønson L; Vikesaa J; Nielsen FC; von Buchwald C
J Pathol; 2015 Aug; 236(4):505-16. PubMed ID: 25925492
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers.
Bhatia S; Oweida A; Lennon S; Darragh LB; Milner D; Phan AV; Mueller AC; Van Court B; Raben D; Serkova NJ; Wang XJ; Jimeno A; Clambey ET; Pasquale EB; Karam SD
Cancer Res; 2019 May; 79(10):2722-2735. PubMed ID: 30894369
[TBL] [Abstract][Full Text] [Related]
15. Biological Significance of EphB4 Expression in Cancer.
Ullah A; Razzaq A; Zhou C; Ullah N; Shehzadi S; Aziz T; Alfaifi MY; Elbehairi SEI; Iqbal H
Curr Protein Pept Sci; 2024; 25(3):244-255. PubMed ID: 37909437
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of EphB4 in mesothelioma and its biological significance.
Xia G; Kumar SR; Masood R; Koss M; Templeman C; Quinn D; Zhu S; Reddy R; Krasnoperov V; Gill PS
Clin Cancer Res; 2005 Jun; 11(12):4305-15. PubMed ID: 15958611
[TBL] [Abstract][Full Text] [Related]
17. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.
Martiny-Baron G; Holzer P; Billy E; Schnell C; Brueggen J; Ferretti M; Schmiedeberg N; Wood JM; Furet P; Imbach P
Angiogenesis; 2010 Sep; 13(3):259-67. PubMed ID: 20803239
[TBL] [Abstract][Full Text] [Related]
18. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB
Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627
[TBL] [Abstract][Full Text] [Related]
19. The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma.
Yavrouian EJ; Sinha UK; Rice DH; Salam MT; Gill PS; Masood R
Arch Otolaryngol Head Neck Surg; 2008 Sep; 134(9):985-91. PubMed ID: 18794445
[TBL] [Abstract][Full Text] [Related]
20. Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.
Bhatia S; Hirsch K; Sharma J; Oweida A; Griego A; Keysar S; Jimeno A; Raben D; Krasnoperov V; Gill PS; Pasquale EB; Wang XJ; Karam SD
Sci Rep; 2016 Dec; 6():38792. PubMed ID: 27941840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
